View : 21 Download: 0

Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein conjugate; Prevenar™) in Korean infants: Differences that are found in Asian children

Title
Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein conjugate; Prevenar™) in Korean infants: Differences that are found in Asian children
Authors
Kim N.-H.Lee J.Lee S.J.Lee H.Kim K.-H.Park S.-E.Lee H.-J.
Ewha Authors
김경효
SCOPUS Author ID
김경효scopus
Issue Date
2007
Journal Title
Vaccine
ISSN
0264-410XJCR Link
Citation
vol. 25, no. 45, pp. 7858 - 7865
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
This study was conducted to determine the immunogenicity and safety of a 7-valent CRM197 protein conjugated pneumococcal vaccine (PCV7) in Korean infants immunized at 2, 4 and 6 months. A total of 202 infants were enrolled and 146 and 141 infants were, respectively, included in post-2nd dose and post-3rd dose immunogenicity evaluations conducted on a per protocol basis. After two and three PCV7 vaccinations, 63.0-98.0 and 97.2-100% of infants achieved an antibody level of ≥0.35 μg/mL, respectively, with a lowest against serotype 6B. No vaccination-related serious adverse reactions were observed. Thus, PCV7 appears safe and highly immunogenic in Korean infants, and adopting two doses for a primary series could be a feasible option for facilitating vaccine coverage rate. © 2007 Elsevier Ltd. All rights reserved.
DOI
10.1016/j.vaccine.2007.08.022
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE